Mesoblast (MESO) Stock Price, News & Analysis

Company Overview

Mesoblast Limited is an Australia-based biotechnology company focused on developing and commercializing regenerative medicines made from specialized allogeneic mesenchymal lineage cells. The company’s platform is designed to produce “off-the-shelf” cellular therapies intended to address inflammation, tissue damage and impaired healing without requiring cells to be collected from each individual patient.

Mesoblast’s lead product, remestemcel-L, is marketed in the United States as RYONCIL. In December 2024, the U.S. Food and Drug Administration approved RYONCIL for the treatment of steroid-refractory acute graft-versus-host disease in pediatric patients two months of age and older. The company has also investigated remestemcel-L and other cellular candidates in conditions including inflammatory diseases, chronic low back pain and heart failure.

Founded in 2004 and headquartered in Melbourne, Australia, Mesoblast conducts research and clinical development activities internationally, with a particular commercial focus on the United States. The company is led by founder and Chief Executive Officer Silviu Itescu, a physician and biotechnology executive who has overseen the development of Mesoblast’s cellular therapy programs.

Key Stats

• Today's Range: $14.20 to $14.81
• 50-Day Range: $11.95 to $18.18
• 52-Week Range: $11.89 to $21.50
• Volume: 171,807 shs
• Average Volume: 234,609 shs
• Market Capitalization: $1.86 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $39.00
• Consensus Rating: Hold

Mesoblast Stock Analysis - MarketRank™

Mesoblast scored higher than 52% of companies evaluated by MarketBeat, and ranked 489th out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Hold

Consensus Rating

Mesoblast has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Mesoblast has a consensus price target of $39.00, representing about 170.1% upside from its current price of $14.44.

Amount of Analyst Coverage

Mesoblast has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Mesoblast are expected to grow in the coming year, from ($0.05) to $0.36 per share.

Price to Book Value per Share Ratio

Mesoblast has a P/B Ratio of 3.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

3.09% of the float of Mesoblast has been sold short.

Short Interest Ratio / Days to Cover

Mesoblast has a short interest ratio ("days to cover") of 13.15, which indicates bearish sentiment.

Change versus previous month

Short interest in Mesoblast has recently decreased by 1.12%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Mesoblast does not currently pay a dividend.

Dividend Growth

Mesoblast does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.30

News Sentiment

Mesoblast has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 17 news articles for Mesoblast this week, compared to 4 articles on an average week.

Search Interest

10 people have searched for MESO on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Mesoblast insiders have not sold or bought any company stock.

Percentage Held by Insiders

18.80% of the stock of Mesoblast is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

1.43% of the stock of Mesoblast is held by institutions.

Company Calendar

• Last Earnings: 7/31/2026
• Today: 11/04/2026
• AGM 2026: 11/09/2026
• Fiscal Year End: 6/30/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:MESO
• Previous Symbol: OTCMKTS:MBLTY
• CIK: 1345099
• Web: www.mesoblast.com
• Phone: (139) 639-6036
• Fax: 61-3-9639-6030
• Employees: 108
• Year Founded: 2004

Price Target and Rating

• Average Price Target for Mesoblast: $39.00
• High Price Target: $39.00
• Low Price Target: $39.00
• Potential Upside/Downside: +172.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.19
• Current Ratio: 2.43
• Quick Ratio: 2.09

Sales & Book Value

• Annual Sales: $120.25 million
• Price / Sales: 15.46
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.38 per share
• Price / Book: 3.26

Miscellaneous

• Outstanding Shares: 130,130,000
• Free Float: 105,666,000
• Market Cap: $1.86 billion
• Optionable: Optionable
• Beta: 2.21